Critical Analysis: Ono Pharmaceutical (OTCMKTS:OPHLF) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Ono Pharmaceutical (OTCMKTS:OPHLF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Recordati Industria Chimica E Farmaceutica and Ono Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.53 billion	N/A	$450.70 million	$3.17	20.64
Ono Pharmaceutical	$3.20 billion	2.74	$330.31 million	$0.89	20.98

Recordati Industria Chimica E Farmaceutica has higher earnings, but lower revenue than Ono Pharmaceutical. Recordati Industria Chimica E Farmaceutica is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Ono Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	N/A	N/A	N/A
Ono Pharmaceutical	12.29%	7.76%	5.91%

Risk & Volatility

Recordati Industria Chimica E Farmaceutica has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Recordati Industria Chimica E Farmaceutica and Ono Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	2	3.33
Ono Pharmaceutical	0	0	0	0	0.00

Summary

Ono Pharmaceutical beats Recordati Industria Chimica E Farmaceutica on 5 of the 9 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.